{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma&page=28&q=advanced+melanoma", "query": { "q": "advanced melanoma", "condition": "Melanoma", "page": 28 }, "page_size": 10 }, "pagination": { "page": 28, "page_size": 10, "total_count": 832, "total_pages": 84, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma&page=29&q=advanced+melanoma&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma&page=27&q=advanced+melanoma&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T01:55:08.601Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01585415", "title": "Vemurafenib and White Blood Cell Therapy for Advanced Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Cancer", "Melanoma" ], "interventions": [ { "name": "Vemurafenib", "type": "DRUG" }, { "name": "Young TIL", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Aldesleukin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "66 Years", "sex": "ALL", "summary": "18 Years to 66 Years" }, "enrollment_count": 12, "start_date": "2012-04-09", "completion_date": "2016-07-21", "has_results": false, "last_update_posted_date": "2019-11-21", "last_synced_at": "2026-10-16T01:55:08.601Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01585415" }, { "nct_id": "NCT01584648", "title": "A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" }, { "name": "Trametinib placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 423, "start_date": "2012-05-04", "completion_date": "2019-02-28", "has_results": true, "last_update_posted_date": "2021-02-17", "last_synced_at": "2026-10-16T01:55:08.601Z", "location_count": 19, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 15 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01584648" }, { "nct_id": "NCT02307149", "title": "Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "CAVATAK", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Viralytics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2015-05-05", "completion_date": "2019-11-05", "has_results": false, "last_update_posted_date": "2023-01-17", "last_synced_at": "2026-10-16T01:55:08.601Z", "location_count": 11, "location_summary": "Duarte, California • La Jolla, California • Los Angeles, California + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02307149" }, { "nct_id": "NCT05709821", "title": "IMM60 and Pembrolizumab in Melanoma and NSCLC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer", "Melanoma" ], "interventions": [ { "name": "IMM60", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "iOx Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2023-11-15", "completion_date": "2024-04-22", "has_results": false, "last_update_posted_date": "2024-04-24", "last_synced_at": "2026-10-16T01:55:08.601Z", "location_count": 5, "location_summary": "Los Angeles, California • Boston, Massachusetts • Detroit, Michigan + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05709821" }, { "nct_id": "NCT06246149", "title": "Adjuvant Tebentafusp in High Risk Ocular Melanoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Uveal Melanoma" ], "interventions": [ { "name": "Tebentafusp", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "European Organisation for Research and Treatment of Cancer - EORTC", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 290, "start_date": "2024-11-11", "completion_date": "2032-11", "has_results": false, "last_update_posted_date": "2026-06-30", "last_synced_at": "2026-10-16T01:55:08.601Z", "location_count": 1, "location_summary": "Lake Success, New York", "locations": [ { "city": "Lake Success", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06246149" }, { "nct_id": "NCT07819474", "title": "Optimizing Tumor-Infiltrating Lymphocyte (TIL) Harvest Site and Patient Selection With CD8-PET Imaging in Patients With", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Tumor Infiltrating Lymphocyte", "CD8-PET", "Advanced Melanoma" ], "interventions": [ { "name": "Crefmirlimb", "type": "DRUG" }, { "name": "PET/CT imaging", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2027-02-18", "completion_date": "2030-08-31", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-10-16T01:55:08.601Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07819474" }, { "nct_id": "NCT05969860", "title": "At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Anal Carcinoma", "Advanced Biliary Tract Carcinoma", "Advanced Bladder Carcinoma", "Advanced Breast Carcinoma", "Advanced Carcinoid Tumor", "Advanced Cervical Carcinoma", "Advanced Colorectal Carcinoma", "Advanced Gastric Carcinoma", "Advanced Glioblastoma", "Advanced Head and Neck Carcinoma", "Advanced HER2 Positive Breast Carcinoma", "Advanced Lung Carcinoma", "Advanced Lung Small Cell Carcinoma", "Advanced Malignant Germ Cell Tumor", "Advanced Malignant Solid Neoplasm", "Advanced Neuroendocrine Carcinoma", "Advanced Ovarian Carcinoma", "Advanced Pancreatic Carcinoma", "Advanced Prostate Small Cell Neuroendocrine Carcinoma", "Advanced Prostate Carcinoma", "Hematopoietic and Lymphoid System Neoplasm", "Multiple Myeloma", "Myelodysplastic Syndrome", "Advanced Basal Cell Carcinoma", "Advanced Cholangiocarcinoma", "Advanced Endometrial Carcinoma", "Advanced Esophageal Carcinoma", "Advanced Fallopian Tube Carcinoma", "Advanced Hepatocellular Carcinoma", "Advanced Liver Carcinoma", "Advanced Lymphoma", "Advanced Malignant Testicular Neoplasm", "Advanced Melanoma", "Advanced Merkel Cell Carcinoma", "Advanced Penile Carcinoma", "Advanced Primary Malignant Central Nervous System Neoplasm", "Advanced Renal Cell Carcinoma", "Advanced Sarcoma", "Advanced Skin Squamous Cell Carcinoma", "Advanced Urethral Carcinoma", "Advanced Vaginal Carcinoma", "Advanced Vulvar Carcinoma", "Advanced Appendix Carcinoma", "Advanced Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "Clinical Encounter", "type": "PROCEDURE" }, { "name": "Home Health Encounter", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 220, "start_date": "2023-08-23", "completion_date": "2027-01-01", "has_results": false, "last_update_posted_date": "2026-04-20", "last_synced_at": "2026-10-16T01:55:08.601Z", "location_count": 2, "location_summary": "Jacksonville, Florida • Grand Forks, North Dakota", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Grand Forks", "state": "North Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05969860" }, { "nct_id": "NCT06075524", "title": "Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Locally Advanced Lung Carcinoma", "Locally Advanced Malignant Solid Neoplasm", "Locally Advanced Melanoma", "Metastatic Lung Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Stage III Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Electronic Health Record Review", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 500, "start_date": "2015-06-15", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-10-16T01:55:08.601Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06075524" }, { "nct_id": "NCT06594991", "title": "A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Melanoma" ], "interventions": [ { "name": "Fianlimab", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 88, "start_date": "2024-09-10", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-16T01:55:08.601Z", "location_count": 12, "location_summary": "Los Angeles, California • Stanford, California • Hartford, Connecticut + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT06594991" }, { "nct_id": "NCT02709889", "title": "Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Malignant Melanoma", "Medullary Thyroid Cancer", "Glioblastoma", "Large-Cell Neuroendocrine Carcinoma", "Neuroendocrine Prostate Cancer", "High Grade Gastroenteropancreatic Neuroendocrine Carcinoma", "Other Neuroendocrine Carcinoma", "Other Solid Tumors" ], "interventions": [ { "name": "Rovalpituzumab tesirine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 200, "start_date": "2016-09-23", "completion_date": "2019-08-27", "has_results": true, "last_update_posted_date": "2020-10-19", "last_synced_at": "2026-10-16T01:55:08.601Z", "location_count": 30, "location_summary": "Gilbert, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "West Hollywood", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02709889" } ] }